keyword
MENU ▼
Read by QxMD icon Read
search

RCC

keyword
https://www.readbyqxmd.com/read/29332335/clinicopathological-characteristics-and-survival-in-serbian-patients-with-renal-cell-carcinoma-a-retrospective-analysis
#1
Ivan Pavlovic, Snezana Pejic, Sofija Glumac, Ana Todorovic, Vesna Stojiljkovic, Natasa Popovic, Ljubica Gavrilovic, Snezana B Pajovic, Sanja Radojevic-Skodric, Zoran Dzamic, Gordana Basta-Jovanovic
PURPOSE: Indications of kidney cancer outcome in lowerincome countries are based on an incidence/mortality ratio due to lack of survival information. This study was conducted to provide outcome data in Serbian patients with renal cell carcinoma (RCC) and to identify prognostic factors that could affect their overall survival (OS). METHODS: This retrospective study included 185 patients who underwent nephrectomy. We assessed certain clinicopathological data including age, gender, tumor size, grade, stage and histological subtypes for their possible impact on OS...
November 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29332133/fumarate-hydratase-fh-deficiency-in-uterine-leiomyomas-recognition-by-histological-features-versus-blind-immunoscreening
#2
Lisa Siegler, Ramona Erber, Stefanie Burghaus, Tobias Brodkorb, David Wachter, Nafisa Wilkinson, James Bolton, Helen Stringfellow, Florian Haller, Matthias W Beckmann, Arndt Hartmann, Abbas Agaimy
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome is a rare autosomal dominant disease caused by germline mutations in the fumarate hydratase (FH) gene. Affected individuals develop cutaneous and uterine leiomyomas and aggressive RCC. To date, only few publications described the frequency and morphology of FH-deficient uterine leiomyomas. We reviewed 22 cases collected over 8 years from routine and consultation files based on distinctive histological features. In addition, we screened 580 consecutive uterine leiomyomas from 484 patients, 23 extra-uterine and 8 uterine leiomyosarcomas, and 6 leiomyomas with bizarre nuclei for FH loss using immunohistochemistry (IHC) on tissue microarrays (TMAs)...
January 13, 2018: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/29331568/overall-survival-and-oncological-outcomes-after-partial-nephrectomy-and-radical-nephrectomy-for-ct2a-renal-tumors-a-collaborative-international-study-from-the-french-kidney-cancer-research-network-uroccr
#3
B Reix, J-C Bernhard, J-J Patard, P Bigot, A Villers, E Suer, N S Vuong, G Verhoest, Q Alimi, J-B Beauval, T Benoit, F-X Nouhaud, C Lenormand, N Hamidi, J Cai, M Eto, S Larre, A El Bakhri, G Ploussard, A Hung, N Koutlidis, A Schneider, J Carrouget, S Droupy, S Marchal, A Doerfler, S Seddik, T Matsugasumi, X Orsoni, A Descazeaud, C Pfister, K Bensalah, M Soulie, I Gill, V Flamand
BACKGROUND: Partial nephrectomy (PN) is recommended as first-line treatment for cT1 stage kidney tumors because of a better renal function and probably a better overall survival than radical nephrectomy (RN). For larger tumors, PN has a controversial position due to lack of evidence showing good cancer control. The aim of this study was to compare the results of PN and RN in cT2a stage on overall survival and oncological results. METHOD: A retrospective international multicenter study was conducted in the frame of the French kidney cancer research network (UroCCR)...
January 10, 2018: Progrès en Urologie
https://www.readbyqxmd.com/read/29330204/pazopanib-exposure-relationship-with-clinical-efficacy-and-safety-in-the-adjuvant-treatment-of-advanced-renal-cell-carcinoma
#4
Cora Sternberg, Frede Donskov, Naomi B Haas, Christian Doehn, Paul Russo, Mohamed A Elmeliegy, Guillaume Baneyx, Hiya Banerjee, Paola Aimone, Robert J Motzer
PURPOSE: PROTECT, a phase III randomized placebo-controlled study, evaluated pazopanib efficacy and safety in the adjuvant RCC setting. The relationship between pazopanib exposure (Ctrough) and efficacy and safety was evaluated. EXPERIMENTAL DESIGN: Evaluable steady-state blood trough concentrations were collected from 311 patients at week 3 or 5 (early Ctrough), and 250 patients at week 16 or 20 (late Ctrough). Pazopanib pharmacokinetic (PK) data was analyzed via a population model approach...
January 12, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29328477/knockdown-of-ubiquitin%C3%A2-specific-peptidase-39-inhibits-the-malignant-progression-of-human-renal-cell-carcinoma
#5
Yuan Xu, Mei-Rong Zhu, Jing-Yong Zhang, Guo-Min Si, Jia-Ju Lv
Ubiquitin specific peptidase 39 (USP39) serves important roles in mRNA processing and is involved in tumorigenesis of multiple solid malignancies. However, the influence and underlying mechanism of USP39 on human renal cell carcinomas (RCC) remain to be elucidated. The current study investigated the functional roles of USP39 in human RCC cell lines. siRNA‑mediated RNA interference was used to downregulate USP39 in RCC cells. CCK‑8, wound healing and invasion assays were performed to assess the proliferative ability and metastatic potential...
January 11, 2018: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29328409/alpha-gene-upregulates-tfeb-expression-in-renal-cell-carcinoma-with-t-6-11-translocation-which-promotes-cell-canceration
#6
He-Qin Zhan, Shu-Ting Li, Yan Shu, Meng-Meng Liu, Rong Qin, Yan-Li Li, Lin Gan
Renal cell carcinoma (RCC) with t(6;11) translocation has been characterized by the fusion of the Alpha gene with the TFEB gene. However, the underlying molecular mechanisms remain greatly uncharacterized and effective targeted therapy has yet to be identified. In this study, we examined the role of the Alpha gene in this tumor entity and the function of the fusion gene Alpha-TFEB product in vitro and in vivo. Our results revealed that the luciferase activity of Alpha1, Alpha2, Alpha3, Alpha4 and Alpha5 significantly increased compared with that of the pGL3-Basic group (P<0...
January 5, 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29327492/a-five-gene-signature-may-predict-sunitinib-sensitivity-and-serve-as-prognostic-biomarkers-for-renal-cell-carcinoma
#7
Yuan-Lei Chen, Guang-Ju Ge, Chao Qi, Huan Wang, Huai-Lan Wang, Li-Yang Li, Gong-Hui Li, Li-Qun Xia
Sunitinib resistance is, nowadays, the major challenge for advanced renal cell carcinoma patients. Illuminating the potential mechanisms and exploring effective strategies to overcome sunitinib resistance are highly desired. We constructed a reliable gene signature which may function as biomarkers for prediction of sunitinib sensitivity and clinical prognosis. The gene expression profiles were obtained from The Cancer Genome Atlas database. By performing GEO2R analysis, numerous differentially expressed genes (DEGs) were found to be associated with sunitinib resistance...
January 12, 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29325434/collection-of-real-world-data-on-nivolumab-s-effectiveness-in-renal-cell-carcinoma-rationale-for-an-observational-study
#8
Jens Bedke, Marc-Oliver Grimm, Viktor Grünwald
Renal cell carcinoma (RCC) represents the seventh (men) respectively tenth (women) most frequent cancer in western countries. After one or more lines of VEGF-targeted therapy, immunotherapy with nivolumab is strongly recommended in patients with metastatic RCC. Nivolumab is the first, and so far, only approved programmed death 1 (PD-1) immune checkpoint inhibitor to demonstrate a gain in overall survival in RCC. We describe herein design and rationale of trial CA209653 ('NIS NORA'), a prospective, noninterventional cohort study investigating the effectiveness of nivolumab...
January 12, 2018: Future Oncology
https://www.readbyqxmd.com/read/29325357/-impact-of-primary-tumor-site-on-the-prognosis-in-different-stage-colorectal-cancer-patients-after-radical-resection
#9
J Han, X Zhang, A D Zhang, X L Zhou, L Feng, J Y Wang, G Y Wang
Objective: To analyze the effect to the prognosis of tumor site on the patients of colorectal cancer after curative resection with different stage. Methods: Clinicopathological and follow-up data of 2 097 colorectal carcinoma cases undergoing resection at Fourth Hospital of Hebei Medical University from January 2008 to March 2015 were retrospectively analyzed. There were 421 patients in left-sided colorectal cancer (LCC) group (including carcinoma in cecum, ascending colon , hepatic flexure, and transvers colon) , 386 in right-sided colorectal cancer (RCC) group (including carcinoma in splenic flexure, descending colon and sigmoid colon) and 1 290 in rectal cancer (RECC) group...
January 1, 2018: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://www.readbyqxmd.com/read/29323560/the-prospects-for-combination-therapy-with-capecitabine-in-the-rapidly-evolving-treatment-landscape-of-renal-cell-carcinoma
#10
Mehmet Asim Bilen, Jennifer Wilkinson-Carlisle, Guru Sonpavde
Although significant advances have been made in the treatment of advanced renal cell carcinoma (RCC), patients still develop resistance to standard therapies and require the administration of subsequent lines of treatment. New therapeutic approaches are thus imperative to improve the prognosis for patients with RCC. Areas covered: Based on the current literature, we summarize the treatment of metastatic RCC, including the use of cytotoxic chemotherapy, in this review article. We also review the existing scientific literature regarding the role of capecitabine in the treatment of RCC...
January 11, 2018: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/29323078/renal-cell-carcinoma-with-t-6-11-a-case-report-and-review-of-literature
#11
K S Jansi Prema, K S Devanathan, Anila Abraham Kurien
Renal cell carcinomas (RCCs) with t(6,11) are very rare tumours. Only a few cases have been reported so far. t(6,11) results in fusion of alpha gene and transcription factor EB (TFEB) gene resulting in the overexpression of TFEB. The specific light and immunohistochemical features help in the diagnosis of this rare type of tumor. We report a case of t(6,11) RCC in a 38-year-old female who was incidentally found to have a right renal mass. We present this case to emphasize the typical light microscopic picture of this extremely rare tumor...
October 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29319926/the-role-of-lymph-node-dissection-in-the-management-of-renal-cell-carcinoma-a-systematic-review-and-meta-analysis
#12
REVIEW
Bimal Bhindi, Christopher J D Wallis, Stephen A Boorjian, R Houston Thompson, Ann Farrell, Simon P Kim, Jose A Karam, Umberto Capitanio, Dragan Golijanin, Bradley C Leibovich, Boris Gershman
OBJECTIVES: To evaluate the role of retroperitoneal lymph node dissection (LND) in non-metastatic (M0) and metastatic (M1) renal cell carcinoma (RCC). PATIENTS AND METHODS: We searched Medline, EMBASE, Web of Science, and Scopus from database inception to August 29, 2017 for studies of patients who underwent partial or radical nephrectomy for M0 or M1 RCC. Two investigators independently selected studies for inclusion. Risk of bias was assessed using the Newcastle-Ottawa scale, Cochrane Collaboration tool, and NHLBI Quality Assessment Tool...
January 10, 2018: BJU International
https://www.readbyqxmd.com/read/29317731/renal-capsular-invasion-is-a-prognostic-biomarker-in-localized-clear-cell-renal-cell-carcinoma
#13
U-Syn Ha, Kyu Won Lee, Jin-Hyung Jung, Seok-Soo Byun, Cheol Kwak, Jinsoo Chung, Eu Chang Hwang, Yong-June Kim, Tae Gyun Kwon, Seok Ho Kang, Sung-Hoo Hong
Renal capsular invasion (RCI) and lymphovascular invasion (LVI) are potential prognostic factors of significance in renal cell carcinoma (RCC). We evaluated the independent prognostic implications of RCI and LVI in localized clear cell RCC based on a large multi-institutional cohort. 6, 849 patients who had undergone radical or partial nephrectomy for RCC were included. Associations between recurrence and RCI or LVI were analyzed by constructing statistical models that combined Cox proportional hazard regression and propensity score matching...
January 9, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29317515/intratumoural-heterogeneity-may-hinder-precision-medicine-strategies-in-patients-with-clear-cell-renal-cell-carcinoma
#14
Maria Rosaria Raspollini, Ilaria Montagnani, Rodolfo Montironi, Francesca Castiglione, Guido Martignoni, Liang Cheng, Antonio Lopez-Beltran
Clear cell renal cell carcinoma (ccRCC) is an heterogeneous tumour at architectural, cellular and molecular level, a reason why the 2014 International Society of Urological Pathology consensus recommended wide sampling of RCC masses to include at least 1 block/cm of tumour together with perpendicular sections of the tumour/perinephric fat interface and the tumour/renal sinus interface. Intratumoural molecular heterogeneity may be a limitation at the moment of defining precision medicine strategies based on gene mutation status...
January 9, 2018: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/29316711/renal-cell-carcinoma-perfusion-before-and-after-radiofrequency-ablation-measured-with-dynamic-contrast-enhanced-mri-a-pilot-study
#15
Tze Min Wah, Steven Sourbron, Daniel Jonathan Wilson, Derek Magee, Walter Martin Gregory, Peter John Selby, David L Buckley
AIM: To investigate if the early treatment effects of radiofrequency ablation (RFA) on renal cell carcinoma (RCC) can be detected with dynamic contrast enhanced (DCE)-MRI and to correlate RCC perfusion with RFA treatment time. MATERIALS AND METHODS: 20 patients undergoing RFA of their 21 RCCs were evaluated with DCE-MRI before and at one month after RFA treatment. Perfusion was estimated using the maximum slope technique at two independent sittings. Total RCC blood flow was correlated with total RFA treatment time, tumour location, size and histology...
January 8, 2018: Diagnostics
https://www.readbyqxmd.com/read/29312589/g6pd-promotes-renal-cell-carcinoma-proliferation-through-positive-feedback-regulation-of-p-stat3
#16
Qiao Zhang, Zhe Yang, Qiaoqiao Han, Honggang Bai, Yanling Wang, Xiaojia Yi, Zihan Yi, Lijuan Yang, Lu Jiang, Xin Song, Yingmin Kuang, Yuechun Zhu
Ectopic Glucose 6-phosphate dehydrogenase (G6PD) expression plays important role in tumor cell metabolic reprogramming and results in poor prognosis of multiple malignancies. Our previous study indicated that G6PD is overexpressed in clear cell renal cell carcinoma (ccRCC), the most common subtype of RCC. However, its role in RCC is still unclear. Here, we demonstrate that G6PD is not only up-regulated in all types of RCC specimens but also displays higher activities in RCC cell lines. G6PD overexpression promoted RCC cell proliferation, altered cell cycle distribution, and enhanced xenografted RCC development...
December 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29311016/the-development-of-brain-metastases-in-patients-with-renal-cell-carcinoma-epidemiologic-trends-survival-and-clinical-risk-factors-using-a-population-based-cohort
#17
Maxine Sun, Guillermo De Velasco, Priscilla K Brastianos, Ayal A Aizer, Allison Martin, Raphael Moreira, Paul L Nguyen, Quoc-Dien Trinh, Toni K Choueiri
BACKGROUND: The incidence of brain metastases (BM) in patients with renal cell carcinoma (RCC) is hypothesized to have increased in the last 2 decades. OBJECTIVE: To define incidence trends according to patient and clinical characteristics, to identify risk factors, and to describe outcomes of patients with BM for RCC. DESIGN, SETTING, AND PARTICIPANTS: Patients diagnosed with RCC between the years 2010 and 2013 within the Surveillance, Epidemiology, and End Results database...
January 5, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29309984/headache-resolution-after-rathke-cleft-cyst-resection-a-meta-analysis
#18
Njoud Altuwaijri, David J Cote, Nayan Lamba, Walaa Albenayan, Steven P Ren, Iman Zaghloul, Joanne Doucette, Hasan A Zaidi, Rania A Mekary, Timothy R Smith
INTRODUCTION: Rathke's cleft cysts (RCC) are benign lesions of the sella that often present with headache. It is not currently well-established whether surgical resection of RCC results in resolution of headache. We conducted a meta-analysis to examine the effect of RCC resection on headache resolution. METHODS: PubMed, EMBASE, and Cochrane databases were searched through June 2017 for articles that evaluated the effect of RCC resection on headache resolution. Pooled effect estimates were calculated using fixed- and random-effects models...
January 5, 2018: World Neurosurgery
https://www.readbyqxmd.com/read/29309300/reappraisal-of-morphologic-differences-between-renal-medullary-carcinoma-collecting-duct-carcinoma-and-fumarate-hydratase-deficient-renal-cell-carcinoma
#19
Chisato Ohe, Steven C Smith, Deepika Sirohi, Mukul Divatia, Mariza de Peralta-Venturina, Gladell P Paner, Abbas Agaimy, Mitual B Amin, Pedram Argani, Ying-Bei Chen, Liang Cheng, Maurizio Colecchia, Eva Compérat, Isabela Werneck da Cunha, Jonathan I Epstein, Anthony J Gill, Ondřej Hes, Michelle S Hirsch, Wolfram Jochum, Lakshmi P Kunju, Fiona Maclean, Cristina Magi-Galluzzi, Jesse K McKenney, Rohit Mehra, Gabriella Nesi, Adeboye O Osunkoya, Maria M Picken, Priya Rao, Victor E Reuter, Paulo Guilherme de Oliveira Salles, Luciana Schultz, Satish K Tickoo, Scott A Tomlins, Kiril Trpkov, Mahul B Amin
Renal medullary carcinomas (RMCs) and collecting duct carcinomas (CDCs) are rare subsets of lethal high-stage, high-grade distal nephron-related adenocarcinomas with a predilection for the renal medullary region. Recent findings have established an emerging group of fumarate hydratase (FH)-deficient tumors related to hereditary leiomyomatosis and renal cell carcinoma (HLRCC-RCCs) syndrome within this morphologic spectrum. Recently developed, reliable ancillary testing has enabled consistent separation between these tumor types...
January 5, 2018: American Journal of Surgical Pathology
https://www.readbyqxmd.com/read/29309249/cabozantinib-a-new-standard-of-care-for-patients-with-advanced-renal-cell-carcinoma-and-bone-metastases-subgroup-analysis-of-the-meteor-trial
#20
Bernard Escudier, Thomas Powles, Robert J Motzer, Thomas Olencki, Osvaldo Arén Frontera, Stephane Oudard, Frederic Rolland, Piotr Tomczak, Daniel Castellano, Leonard J Appleman, Harry Drabkin, Daniel Vaena, Steven Milwee, Jillian Youkstetter, Julie C Lougheed, Sergio Bracarda, Toni K Choueiri
Purpose Cabozantinib, an inhibitor of tyrosine kinases including MET, vascular endothelial growth factor receptors, and AXL, increased progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in patients with advanced renal cell carcinoma (RCC) after previous vascular endothelial growth factor receptor-targeted therapy in the phase III METEOR trial. Because bone metastases are associated with increased morbidity in patients with RCC, bone-related outcomes were analyzed in METEOR...
January 8, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
10482
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"